Kalaris Therapeutics announces director resignation and election of Laurie Keating

Kalaris Therapeutics, Inc.

Morana Jovan-Embiricos resigned from board and audit committee effective July 3, 2026; no disagreement with company.
Laurie Keating elected as Class I director effective August 1, 2026, and appointed to audit committee.
Keating receives option for 18,000 shares vesting over 3 years, annual cash $40,000 board plus $7,500 audit committee.
Keating will enter standard indemnification agreement; compensation per non-employee director policy.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Laurie Keating

Director

KLRS · Kalaris Therapeutics, Inc.

Effective: 2026-08-01
Filed: July 6, 2026, 4:11 PM ET

On July 3, 2026, upon the recommendation of the Nominating and Corporate Governance Committee of the Board, the Board elected Laurie Keating to serve as a member of the Board, effective as of August 1, 2026.

Departed

Morana Jovan-Embiricos

Director

KLRS · Kalaris Therapeutics, Inc.

Effective: 2026-07-03
Successor: Laurie Keating
Filed: July 6, 2026, 4:11 PM ET

On July 3, 2026, Morana Jovan-Embiricos, Ph.D., notified Kalaris Therapeutics, Inc. (the “Company”) of her decision to resign as a member of the Company’s board of directors (the “Board”), effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Laurie Keating was elected as Director at Kalaris Therapeutics, Inc..

Action: elected
Role: Director

Exact text from the filing

On July 3, 2026, upon the recommendation of the Nominating and Corporate Governance Committee of the Board, the Board elected Laurie Keating to serve as a member of the Board, effective as of August 1, 2026.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Morana Jovan-Embiricos resigned as Director at Kalaris Therapeutics, Inc..

Action: resigned
Role: Director

Exact text from the filing

On July 3, 2026, Morana Jovan-Embiricos, Ph.D., notified Kalaris Therapeutics, Inc. (the “Company”) of her decision to resign as a member of the Company’s board of directors (the “Board”), effective immediately.

View on SEC.gov

Kalaris Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-296190

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.